Latest ArticlesAs the first mitogen-activated protein kinase kinase kinase 5(MAP3K5) inhibitor in the clinical stage, indications of selonsertib in clinical trials included non-alcoholic steatohepatitis, pulmonary arterial hypertension and diabetic kidney disease. Due to its novel and unique structure, it has become the main lead compound for structural design and backbone modification of this class of inhibitors. In recent years, a large number of “me-too” candidates had been obtained from selonsertib by the structure modification. This paper introduces the progress of structure modification strategies and structure-activity relationships of selonsertib from two aspects of skeleton fragment modification and cyclization structure modification, aiming to provide a reference for research in this field.
Antibody-drug conjugates (ADC) combine the targeting ability of monoclonal antibodies and the potent cytotoxicity of small molecule substances, becoming a research focus in the current biopharmaceutical field. Although various ADCs have been marketed globally, challenges still exist in formulation and stability. This review outlines the key points and difficulties in ADC formulation development and clinical application from the perspectives of antibody, linker, and small molecule substance selection for ADC, and proposes a stability study plan during ADC use, aiming to provide references for the future ADC development.
This review introduces the principles, structures and development directions of commonly used ultrafine pulverizing equipment. The application of ultrafine pulverization technology in preparation of traditional Chinese medicines is systematically outlined, including enhancing the wall breaking rate, refining the physicochemical properties, promoting the extraction, elevating the efficacy of medicinal components, and streamlining subsequent processing of traditional Chinese medicines. Then, the combining principles of particle design technology with traditional Chinese medicine powder technology are elucidated. Additionally, methods for determining particle size and evaluating cell wall breaking rates, as well as the conduction of pharmacokinetic-pharmacodynamic studies of traditional Chinese medicine ultrafine powder are proposed. Ultimately, the development prospects of ultrafine pulverization technology are discussed, and the issues that urgently need resolution are summarized, with the aim of providing references for the application of ultrafine pulverization technology in preparation of traditional Chinese medicines.
Microneedle is a painless transdermal drug delivery system that has become a hot topic in drug formulation development in recent years due to its numerous advantages of avoiding the first-pass effect, maintaining smooth blood concentration, and providing high bioavailability, good safety and patient compliance. However, despite these benefits, there are several challenges associated with microneedle technology, including poor biocompatibility, limited drug loading capacity, unstable drug release, and restricted mechanical properties. The microneedle materials play a crucial role in determining the direction of clinical applications, drug-loading capability, and drug stability. This review summarizes and organizes the research progress made in the field of various new microneedle materials, as well as highlights their potential applications and prospects, hoping to provide a valuable reference for the development of microneedle formulations.
In recent years, with the frequent occurrence of respiratory diseases such as chronic obstructive pulmonary disease and asthma, pulmonary administration has gradually become a new trend in the treatment of these diseases. And inhalation administration is one of the more widely used ways. In the development of inhalation, there is often a certain amount of amorphous material present in the active pharmaceutical ingredients, excipients, and intermediates due to the processes such as micronization and grinding. Amorphous material has poor thermal stability and can easily transform into the crystalline under certain conditions, which can potentially cause many issues, such as affecting the stability of the final products. Therefore, whether it is a single compound or an intermediate obtained according to a prescription, a mature drug development process must include the detection and quantitative analysis of amorphous material in the drug. This review mainly elaborates on the detection methods commonly used in the pharmaceutical field for the amorphous content.
Technology transfer is crucial throughout the entire lifecycle of biological macromolecules. Given the intricate structure and the unpredictable production of biological macromolecules, this review categorizes the technology transfer of production process of biological macromolecules into two phases: preclinical and early clinical sample production, as well as pivotal clinical and commercialization stage sample production. Depending on the objectives and tasks of each phase, key control points for technology transfer in production processes, encompassing cell lines, raw materials, production processes, safety evaluation of exogenous factors, and comparability studies, are identified. And the corresponding technology transfer strategies are suggested, accompanied by a compilation of common challenges faced during the technology transfer process of biological macromolecules, with the aim to serve as a guide for biopharmaceutical companies in their technology transfer for production process.
4-Bromo-3-(1,3-dioxolane-2-yl)phenol(3) was synthesized by condensation of 2-bromo-5-hydroxybenzaldehyde(2) with ethylene glycol in toluene under the catalysis of p-toluenesulfonic acid and pyridine. The addition of pyridine buffered the acidity of p-toluenesulfonic acid and solved the problems of reversible reaction and polymer formation. 4-[4-Bromo-3-(1,3-dioxolane-2-yl)phenoxy]benzonitrile(4) was synthesized from 3 and 4-fluorobenzonitrile under the action of anhydrous potassium carbonate and tetrabutylammonium bromide. The phase transfer catalyst made the reaction faster. 4-(4-Bromo-3-formylphenoxy)benzonitrile(5) was obtained by deprotection of 4. Miyaura borylation of 5 with bis(pinacolato)diboron catalyzed by [1,1'-bis(diphenylphosphino) ferrocene]-dichloropalladium[Pd(dppf)Cl2] produced 4-[3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-benzonitrile(6), which avoided the flammable and explosive reagents and intermediates and strict operation conditions. After reduction with sodium borohydride, crisaborole(1) was obtained by cyclization. Sodium borohydride was added dropwise in the form of aqueous solution(containing 5% NaOH) to make the operation safer and more convenient. The total yield of the improved synthesis was 51.7%(based on 2), with the purity more than 99.9%.